Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial |
| |
| Affiliation: | 1. Department of Dermatology, Stanford University School of Medicine, Redwood City, California;2. Department of Internal Medicine, University of California, Riverside, California;3. University of California, Irvine School of Medicine, Irvine, California;4. Menlo Therapeutics Inc (formerly Tigercat Pharma, Inc), Redwood City, California |
| |
| Abstract: | ![]()
|
| |
| Keywords: | chronic itch drug response epidermolysis bullosa neurokinin 1 receptor NK1 receptor NK1 receptor antagonist pruritus serlopitant substance P AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0060" }," $$" :[{" #name" :" text" ," _" :" adverse event EB" },{" #name" :" keyword" ," $" :{" id" :" kwrd0070" }," $$" :[{" #name" :" text" ," _" :" epidermolysis bullosa NRS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" Numeric Rating Scale RDEB" },{" #name" :" keyword" ," $" :{" id" :" kwrd0090" }," $$" :[{" #name" :" text" ," _" :" recessive dystrophic epidermolysis bullosa SAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0100" }," $$" :[{" #name" :" text" ," _" :" serious adverse event SP-NK1R" },{" #name" :" keyword" ," $" :{" id" :" kwrd0110" }," $$" :[{" #name" :" text" ," _" :" substance P-neurokinin 1 receptor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
